[Skip to Navigation]
December 1949

AUREOMYCIN TREATMENT OF PNEUMOCOCCIC PNEUMONIA: Clinical and Laboratory Studies on Thirty-Three Patients

Author Affiliations

Research Fellow in Medicine, Harvard Medical School, and Research Fellow, Thorndike Memorial Laboratory; Milton Fellow, Harvard Medical School, and Research Fellow, Thorndike Memorial Laboratory; Associate Professor of Medicine, Harvard Medical School; Chief, Fourth Medical Service and Associate Physician, Thorndike Memorial Laboratory, Boston City Hospital BOSTON

From the Thorndike Memorial Laboratory, Second and Fourth Medical Services (Harvard), Boston City Hospital and the Department of Medicine, Harvard Medical School.

Arch Intern Med (Chic). 1949;84(6):857-874. doi:10.1001/archinte.1949.00230060014002

AUREOMYCIN is an antibiotic which, from the results of early studies in vitro and in experimental infections, as well as in initial clinical trials, appears to have a wider range of activity than its successful antecedents, penicillin and streptomycin.1 This range encompasses most of the known causative agents of the acute pneumonias, including the gram-positive and gram-negative bacteria, the organisms of the psittacosis-lymphogranuloma venereum group and the Q fever and other rickettsias. Since aureomycin was also found to be effective when given by mouth and was essentially free of serious toxic effects, it seemed particularly suitable for extended clinical trials in cases of pneumonias of diverse origin. During the past year an attempt was therefore made to evaluate the therapeutic effectiveness of aureomycin in the various types of pneumonia and in some of the other severe acute infections of the respiratory tract that were available for study. The present

Add or change institution